Windtree Therapeutics receives offer for preclinical oncology drug candidate

Windtree Therapeutics (WINT) has received a non-binding letter of intent to purchase its preclinical oncology aPKCi inhibitor platform for $7M dollars up front in cash or freely tradable stock and up to $130 in milestone payments and high, single digit royalties up to $1.5B. he agreement also includes options with additional consideratiMon to acquire the Company’s cardiovascular clinical and preclinical stage drug candidates and its agreement to act as the manufacturing agent for Evofem Biosciences for its FDA approved product. As part of the agreement, the Company has 21 days to close the oncology aPKCi portion of the transaction.